drugset / Trial / NCT02092207

Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome

NCT02092207 ↗

Phase 2 Completed 147 enrolled Yungjin Pharm. Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a controlled study to determine the effectiveness and safety of KL7016 in the treatment of adult patients with dry eye syndrome (DES).

Timeline

Start
2012-10
Primary completion
2014-06
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject KL7016 Unknown 600 mg Oral
Subject KL7016 Unknown 900 mg Oral

Indications